Two New Lactones and One New Aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one from *Descurainia sophia*

Kai SUN,^a Xian LI,^{*,a} Wen LI,^b Jinhui WANG,^a Jianming LIU,^c and Yi SHA^b

^a Research Department of Natural Medicine, Shenyang Pharmaceutical University; ^b The Center of Instrumental Analysis, Shenyang Pharmaceutical University; Shenyang 110016, P. R. China; and ^c Research Department, Yisheng Pharmaceutical Co. Ltd.; Ji'an 134200, P. R. China. Received July 4, 2004; accepted September 21, 2004

Two new lactones (1, 2), descurainolide A and B, and one new aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one (3), descurainin, together with five known compounds (4–8), were isolated from the seeds of *Descurainia sophia* (L.) WEBB ex PRANTL. The structures of the new compounds were elucidated by extensive studies of their 1D, 2D NMR and HR-MS. Compounds 4 and 5 showed cytotoxicity.

Key words *Descurainia sophia*; lactone; aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one; nor-lignan; cytotoxicity

Descurainia sophia (L.) WEBB ex PRANTL is widely distributed in the northeast of China, and its seeds are used in China as a Chinese traditional medicine to relieve a cough, prevent asthma, reduce edema, promote urination and have a cardiotonic effect. In some cases the seeds can also be used in the treatment of some cancers.¹⁾ In the previous chemical studies, it was reported the isolation of some cardiac glycosides,²⁾ flavonoids and phenols³⁾ from the seeds. As our current interest in the medicinal uses of the seeds of *D. sophia*, we also carried out a phytochemical investigation on the seeds of *D. sophia*, which resulted in two new lactones, descurainolide A and B (**1**, **2**), and a new aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one, descurainin (**3**), together with five known compounds. All the three new compounds we got possess the same 4-hydroxy-3,5-dimethoxy-phenyl moiety, and sinapic acid moieties or sinapic acid derivate moieties can be found in their structures. Therefore it seems that the three new compounds are related to sinapic acid or sinapic acid derivatives in biosynthesis. As a part of my research, that will be carried out in the future. This paper deals with the isolation and structural elucidation of the new constituents on the base of extensive studies of their 1D and 2D NMR and HR-MS, and cytotoxicity of the isolated compounds towards 6 human cancer cell lines.

The ethanolic extract of the seeds of *D. sophia* was subjected to column chromatography on macroporous resin D101. Separation of the 40% ethanol eluate on a silica open column yielded eight compounds. The known compounds **4**–**8** were determined to be strophanthidin (**4**),⁴⁾ isorhamnetin-3-*O*- β -D-glucopyranoside (**5**),⁵⁾ sinapic acid ethyl ester (**6**),³⁾ isorhamnetin (**7**)⁵⁾ and quercetin-3-*O*- β -D-glucopyranoside (**8**)⁶⁾ by analysis of the physical and spectroscopic evidence, and confirmed by comparing with the literature data.

Compound **1** was obtained as colorless needles. It responded positively to the FeCl₃ reagent. The molecular formula of C₁₃H₁₆O₅ was deduced from HR-ESI-MS spectrum. ¹H-, ¹³C-NMR spectra (Tables 1, 2) and HMQC of **1** indicated a 4-hydroxy-3,5-dimethoxy-phenyl moiety at δ_{H} 3.75 (6H, s), 6.66 (2H, s) and 8.26 (1H, s), δ_{C} 56.1 (2C), 105.3 (2C), 128.6, 134.8 and 148.1 (2C)³⁾; one methyl group at δ_{H} 1.27 (3H, d, 6.0 Hz) which suggested a connection with one methine group, δ_{C} 18.6; a methylene group at δ_{H} 2.92 (1H, dd, 17.1, 11.4 Hz) and 2.76 (1H, dd, 17.1, 8.4 Hz), δ_{C} 37.1; a methine group at δ_{H} 3.17 (1H, m), δ_{C} 49.0; another methine

group attached to an oxygen atom at δ_{H} 4.51 (1H, m), δ_{C} 82.4; and a lactone carbonyl group at δ_{C} 175.6. In addition, six degrees of unsaturation, among which four were attributed to the phenyl moiety and one was caused by the carbonyl group, confirmed the presence of a lactone ring. The deduction of C-5 connecting with the oxygen atom on the lactone ring was supported by the chemical shifts of H-5 and C-5. The connecting order of C-2, C-3, C-4 and C-5, and the substitutions of C-4 by the phenyl group and C-5 by the methyl group were determined, respectively, via HMBC (Fig. 1) which exhibited the cross peaks: C-1' with H-3 α and H-5; C-2 with H-5; C-4 with H-2', 6' and 5-Me. In the NOESY spectrum, the cross peaks: H-4 with 5-Me; H-2', 6' with H-5, revealed the relative configuration of **1**: the *trans*-orientation of the phenyl moiety and 5-Me. Thus, the structure of descurainolide A (**1**) was elucidated as 4-(4-hydroxy-3,5-dimethoxy-phenyl)-5-methyl-dihydro-furan-2-one.

Compound **2** was obtained as colorless needles and responded positively to the FeCl₃ reagent. The HR-ESI-MS of **2** suggested the molecular formula of C₂₁H₂₂O₈. The NMR spectra (Tables 1, 2) and the HMQC spectrum of **2** revealed two 4-hydroxy-3,5-dimethoxy-phenyl moieties³⁾; a double bond group (–CH=C–) at δ_{H} 7.42 (1H, br s), δ_{C} 135.9 and 130.2; a methylene group at δ_{H} 3.69 (1H, br dd, 17.7, 7.2 Hz) and 3.22 (1H, dd, 17.7, 7.2 Hz), δ_{C} 35.4; a methine group substituted by an oxygen atom at δ_{H} 5.52 (1H, t, 7.2 Hz), δ_{C} 78.6; and a lactone carbonyl group at δ_{C} 171.7. Compared with 2-(4-hydroxy-3,5-dimethoxy-phenyl)-4-(4-hydroxy-3,5-dimethoxy-benzylidene)-5-oxo-tetrahydro-furan-3-carboxylic acid (**9**),⁷⁾ it was inferred that **2** possessed the similar structure to **9** and 3-carboxylic acid on the lactone ring of **9** was substituted by a hydrogen atom. The chemical shifts of H-5 and C-5 indicated the carbon to C-5 linked with the oxygen atom belonging to the lactone ring of **2**. In the HMBC spectrum (Fig. 2), the connection of C-7' to C-1', the position of the double bond 3(7'), the substitution of C-5 by C-1'', and the connecting order of the lactone ring were confirmed respectively by the cross peaks: C-7' with H-2', 6'; and C-2', 6' with H-7'; C-2 and C-4 with H-7'; C-2'', 6'' with H-5; and C-5 with H-2'', 6''; C-2 with H-5; and C-1'' with H-4 α , 4 β . The orientation of the double bond 3(7') was supported by comparison with the known compound and the NOESY experiment. The chemical shift of H-7'⁸⁾ and the cross peak of H-2', 6' with H-4 α intimated the *trans*-orientation of the

* To whom correspondence should be addressed. e-mail: lixian@mail.sy.ln.cn

Table 1. ^1H -NMR Spectral Data for Compounds **1**, **2** and **3** (in $\text{DMSO}-d_6$, 300 MHz)^{a)}

H	1	2	3
1			4.51 br d (8.1)
2			
3 α	2.92 dd (17.1, 11.4)		6.19 d (9.9)
3 β	2.76 dd (17.1, 8.4)		
4 α		3.69 br dd (17.7, 7.2)	6.82 d (9.9)
4 β	3.17 m	3.22 dd (17.7, 7.2)	
5	4.51 m	5.52 t (7.2)	
6			3.45 dd (10.2, 7.2)
7 α			2.83 m
7 β			1.92 dd (13.5, 7.2)
2', 6'	6.66 s	6.93 s	6.41 s
7'		7.42 br s	
2'', 6''		6.68 s	
5-CH ₃	1.27 d (6.0)		
5-CH ₂ OH			3.69 dd (12.6, 6.0)
			3.59 dd (12.6, 6.0)
5-CH ₂ -OH			5.12 t (6.0)
3', 5'-OCH ₃	3.75 s	3.80 s	3.71 s
3'', 5''-OCH ₃		3.77 s	
4'-OH	8.26 s	9.08 s	8.28 s
4''-OH		8.51 s	

a) Value in parentheses are coupling constants in Hz.

Table 2. ^{13}C -NMR Spectral Data for Compounds **1**, **2** and **3** (in $\text{DMSO}-d_6$, 75 MHz)

C	1	2	3	C	1	2	3
1			79.7	4'	134.8	138.0	134.8
2	175.6	171.7	196.9	7'		135.9	
3	37.1	130.2	127.1	1''		122.1	
4	49.0	35.4	154.4	2'', 6''		104.1	
5	82.4	78.6	85.8	3'', 5''		148.1 ^{a)}	
6			47.2	4''		135.9	
7			32.9	5-CH ₃	18.6		
1'	128.6	124.8	127.2	5-CH ₂ OH			62.3
2', 6'	105.3	108.2	106.5	3', 5'-OCH ₃	56.1	56.2	56.1
3', 5'	148.1	148.0 ^{a)}	147.7	3'', 5''-OCH ₃		56.2	

a) Interchanged.

HMBC: —————→

NOESY: —————↔

HMBC: —————→

NOESY: —————↔

Fig. 1. Important HMBC Correlations and NOESY Correlations of Compound **1**

Fig. 2. Important HMBC Correlations and NOESY Correlations of Compound **2**

double bond 3(7'). Thus, the structure of descurainolide B (**2**) was elucidated as *trans*-3-(4-hydroxy-3,5-dimethoxy-benzylidene)-5-(4-hydroxy-3,5-dimethoxy-phenyl)-dihydrofuran-2-one. Compound **2** was a new nor-lignan.

Compound **3** was also obtained as colorless needles and positive to the FeCl_3 reagent. The molecular formula of $\text{C}_{16}\text{H}_{18}\text{O}_6$ was deduced from HR-ESI-MS spectrum. Combined with HMQC, its NMR spectra (Tables 1, 2) showed the same 4-hydroxy-3,5-dimethoxy-phenyl moiety as those of **1** and **2**; an α,β -unsaturated carbonyl group on a carbon ring at δ_{H} 6.19 (1H, d, 9.9 Hz) and 6.82 (1H, d, 9.9 Hz), δ_{C} 127.1, 154.4 and 196.9; a hydroxymethyl group at δ_{H} 5.12 (1H, t, 6.0 Hz), 3.69 (1H, dd, 12.6, 6.0 Hz) and 3.59 (1H, dd, 12.6, 6.0 Hz), δ_{C} 62.3; a quaternary carbon atom connected with an oxygen atom at δ_{C} 85.8; a methine group attached to an oxygen atom at δ_{H} 4.51 (1H, brd, 8.1 Hz), δ_{C} 79.7; another methine group at δ_{H} 3.45 (1H, dd, 10.2, 7.2 Hz), δ_{C} 47.2; and a methylene group at δ_{H} 1.92 (1H, dd, 13.5, 7.2 Hz) and 2.83 (1H, m), δ_{C} 32.9. Eight degrees of unsaturation, three attributed to the carbon ring containing the α,β -unsaturated carbonyl group and four to the phenyl group, indicated the presence of a bridged-ring system. Compared with the NMR spectral data of the known 5-hydroxymethyl-6-(4-hydroxy-3-methoxyphenyl)-8-oxa-bicyclo[3,2,1]oct-3-en-2-one,⁹⁾ a rare aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one in nature, a moiety of 8-oxa-bicyclo[3,2,1]oct-3-en-2-one of **3** was suggested. The ^1H - ^1H COSY spectrum exhibited the connections of C-1 with C-7, and C-7 with C-6, by the cross peaks: H-1 with H-7 α , and H-7 β with H-6. In addition, the connecting order of the 8-oxa-bicyclo[3,2,1]oct-3-en-2-one moiety was established by HMBC (Fig. 3), in which the cross peaks: C-1 with H-3; C-2 with H-7 α , 7 β ; C-5 with H-3; C-5 with H-7 α ; C-4 with H-6; C-5 with H-1, confirmed the connections of C-1 to C-2, C-4 to C-5, C-5 to C-6, and C-1 to C-5 by an oxo bridge which made the *cis*-orientation of H-1 and the substituent of C-5 necessary. The positions of the hydroxymethyl group and the phenyl group were determined to be C-5 and C-6, respectively, by the cross peaks of HMBC: C-5 with 5- CH_2OH ; 5- CH_2OH with H-4; C-6 with H-2', 6'; C-2', 6' with H-6. The stereochemistry of **3** was revealed by the NOESY experiment. The cross peaks of H-1 and H-7 α , H-7 α and H-6, H-7 β and H-2', 6' showed the same orientation of H-1, H-6 and H-7 α , and then 5- CH_2OH should also adopt this orientation. Therefore, the relative configuration of **3** was identified as the *trans*-orientation of the phenyl moiety and 5- CH_2OH . Thus, the structure of descurainin (**3**) was elucidated as 5-hydroxymethyl-6-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxa-bicyclo[3,2,1]oct-3-en-2-one.

The cytotoxic potential of the isolated compounds was investigated by determining their concentrations required for 50% growth inhibition (IC_{50} value) for 6 human cancer cell lines. Compounds **4** and **5** showed cytotoxicity (Table 3). Compound **4** exhibited significant cytotoxicity towards human stomach adenocarcinoma cell line, BGC-823 and human breast carcinoma cell line, MDA-MB-435; and moderate activity towards human prostate cancer cell line, PC-3M-1E8, human hepatic carcinoma cell line, Bel-7402 and human cervical cancer cell line, HeLa. Compound **5** showed moderate cytotoxicity only towards human acute myeloid leukemia cell line, HL-60. Other isolated compounds showed no or little cytotoxicity.

Fig. 3. Important HMBC Correlations and NOESY Correlations of Compound **3**

Table 3. Cytotoxicity of Compounds **4** and **5**

Cancer cell lines	IC_{50} of 4 ($\mu\text{g/ml}$)	IC_{50} of 5 ($\mu\text{g/ml}$)
HL-60	>10	2.24
PC-3M-1E8	4.48	>10
BGC-823	2.25×10^{-2}	>10
MDA-MB-435	0.142	>10
Bel-7402	2.34	>10
HeLa	0.541	>10

Experimental

General Melting point was measured on a Yamaco micro-hot-stage and is uncorrected. NMR spectra were recorded on a Bruker-ARX-300 spectrometer, using TMS as an internal standard. ESI-MS was performed on a Finnigan LCQ mass spectrometer. HR-ESI-MS was performed on a QSTAR LCQ mass spectrometer. The optical rotation was measured on a Perkin-Elmer 241 polarimeter. Silica gel for chromatography was produced by Qingdao Ocean Chemical Group Co. Ltd., China. Macroporous resin D101 for chromatography was produced by Nankai University.

Plant Material The plant material was purchased from Shenyang TCM Corporation (Shenyang), and was identified by Prof. Sun Qishi (Shenyang Pharmaceutical University). A voucher specimen (No. 20010321) is deposited in the Research Department of Natural Medicine, Shenyang Pharmaceutical University.

Extraction and Isolation The air-dried seeds (10 kg) of *Descurainia sophia* were extracted three times with 70% ethanol for 2 h each. The extract was concentrated *in vacuo*, chromatographed on a D101 macroporous resin column and eluted with H_2O , 20%, 40%, 60% and 95% ethanol successively. The 40% eluate (100 g) was pre-fractionated by CC on silica gel yielding fraction 1 (CHCl_3 -MeOH 200:1, 1.2 g), fraction 2 (CHCl_3 -MeOH 100:1, 1.0 g) and fraction 3 (CHCl_3 -MeOH 200:3, 1.3 g), compound **7** (CHCl_3 -MeOH 50:1, recrystallized, 235 mg), compound **4** (CHCl_3 -MeOH 100:3, recrystallized, 275 mg), compound **5** (CHCl_3 -MeOH 200:11, recrystallized, 323 mg) and compound **8** (CHCl_3 -MeOH 200:15, recrystallized, 175 mg). Fraction 1 (1.2 g) was separated by CC on silica gel eluting with petroleum ether-EtOAc- Me_2CO to yield compound **6** (15:1:1, recrystallized, 123 mg) and compound **1** (8:1:1, recrystallized, 103 mg). Fraction 2 (1.0 g) and fraction 3 (1.3 g) were purified, respectively, by recrystallization to yield compound **2** (85.7 mg) and compound **3** (59.2 mg).

Descurainolide A (**1**): Colorless needles, mp 117–118 °C; $[\alpha]_{\text{D}}^{20} = +0.3^\circ$ ($c=0.19$, Me_2CO); ESI-MS: m/z 253.0 $[\text{M}+\text{H}]^+$ and 251.0 $[\text{M}-\text{H}]^-$; HR-ESI-MS: m/z 275.0894 $[\text{M}+\text{Na}]^+$ (Calcd for $\text{C}_{13}\text{H}_{16}\text{O}_3\text{Na}$ 275.0895); for NMR spectra, see Tables 1 and 2.

Descurainolide B (**2**): Colorless needles, mp 201–203 °C; $[\alpha]_{\text{D}}^{20} = +2.3^\circ$ ($c=0.37$, MeOH); ESI-MS: m/z 402.8 $[\text{M}+\text{H}]^+$ and 400.9 $[\text{M}-\text{H}]^-$; HR-ESI-MS: m/z 425.1175 $[\text{M}+\text{Na}]^+$ (Calcd for $\text{C}_{21}\text{H}_{22}\text{O}_8\text{Na}$ 425.1212); for NMR spectra, see Tables 1 and 2.

Descurainin (**3**): Colorless needles, mp 193–195 °C; $[\alpha]_{\text{D}}^{20} = +1.7^\circ$ ($c=0.23$, MeOH); ESI-MS: m/z 307.0 $[\text{M}+\text{H}]^+$ and 304.9 $[\text{M}-\text{H}]^-$; HR-

ESI-MS: m/z 329.1011 $[M+Na]^+$ (Calcd for $C_{16}H_{18}O_6Na$ 329.1001); for NMR spectra, see Tables 1 and 2.

In Vitro Cytotoxic Assay The cytotoxicity of the prepared constituents of the seeds of *D. sophia* against human acute myeloid leukemia cell line, HL-60, was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric method; and the activity towards human stomach adenocarcinoma cell line, BGC-823, human breast carcinoma cell line, MDA-MB-435, human prostate cancer cell line, PC-3M-1E8, human hepatic carcinoma cell line, Bel-7402 and human cervical cancer cell line, HeLa was monitored by the sulforhodamine B (SRB) method. Briefly, cells (2.5×10^4 /ml) in RPMI-1640 medium supplemented with 10% fetal bovine serum were incubated in 96-well plates in the presence of serially diluted samples at 37 °C in the 5% CO₂ incubator for 48 h. For the MTT method, cells were incubated with MTT for 4 h. Reduced MTT crystals were dissolved in DMSO, and then the absorbance at 570 nm of each well was measured using an assay plate reader (Tecan, Salzburg, Austria) to determine cell growth inhibition. For the SRB assay, cultured cells fixed with trichloroacetic acid were stained for 30 min with SRB dissolved in 1% acetic acid. Unbound dye was removed by four washes with 1% acetic acid, and protein-bound dye was extracted with 10 mM unbuffered Tris base (pH 10.5) for 5 min. OD value was read at 540 nm in an assay plate reader (Tecan, Salzburg, Austria) to determine cell growth inhibition.

Acknowledgements Special thanks are due to the Analytical Detective Center, Shenyang Pharmaceutical University, for recording MS and NMR spectra.

References

- 1) Sun K., Li X., *Chin. Tradit. Herb. Drugs*, **33**, U 003—005 (2002).
- 2) Chen Y. Q., Li R. Z., Wang Y. W., *Acta Pharm. Sin.*, **16**, 62—64 (1981).
- 3) Wang A. Q., Wang X. K., Li J. L., Cui X. Y., *Acta Pharm. Sin.*, **39**, 46—51 (2004).
- 4) Tori K., Ishii H., Wolkowski Z. W., Chachaty C., *Tetrahedron Lett.*, **13**, 1077—1080 (1973).
- 5) Liang H., Zhao Y. Y., Cui Y. J., Liu Q. X., *J. Beijing Med. Univ.*, **32**, 223—225 (2000).
- 6) Yi X., Shi J. G., Zhou G. X., Xie M. Y., *China J. Chin. Mater. Med.*, **27**, 43—45 (2002).
- 7) Umezawa H., Takeuchi T., Kumada Y., Jpn. Kokai Tokkyo Koho CODEN: JKXXAF JP 52136163 19771114 Showa (1977).
- 8) Niwa T., Doi U., Osawa T., *Bioorg. Med. Chem. Lett.*, **12**, 963—965 (2002).
- 9) Wen Y. S., He Z. R., Xue K. F., Cao F. Y., *Chin. Tradit. Herb. Drugs*, **17**, 122—126 (1986).